Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 4/20 | 0.39 |
| ▸ | SKP1 | P63208 | 4/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | USP1 | O94782 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21259011 | 0.91 | CKS1B (0.38) | CKS1BSKP1SKP2CYP11B2PTPN11 | |
| SCHEMBL21258920 | 0.89 | PTPN11 (0.34) | CKS1BSKP1SKP2CYP11B2PTPN11 | |
| SCHEMBL21258939 | 0.84 | CKS1B (0.38) | CKS1BSKP1SKP2CYP11B2PTPN11 | |
| SCHEMBL21258934 | 0.83 | CKS1B (0.37) | CKS1BSKP1SKP2CYP11B2PTPN11 | |
| SCHEMBL21258878 | 0.82 | KDM4E (0.38) | CKS1BSKP1SKP2CYP11B2GPR119 | |
| SCHEMBL22781926 | 0.80 | MEN1 (0.35) | CKS1BSKP1SKP2CYP11B2USP1 | |
| SCHEMBL21258690 | 0.80 | CKS1B (0.33) | CKS1BSKP1SKP2CYP11B2PTPN11 | |
| SCHEMBL21258886 | 0.80 | MEN1 (0.35) | CKS1BSKP1SKP2CYP11B2RORC | |
| SCHEMBL21259000 | 0.79 | CKS1B (0.36) | CKS1BSKP1SKP2CYP11B2USP1 | |
| SCHEMBL21259003 | 0.78 | PTPN11 (0.36) | PTPN11ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | CKS1B 3575/4885SKP1 2875/4885SKP2 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.